In-Vitro Diagnostics (IVD) Devices: A Complete Guide

What Counts as an IVD?

• In vitro diagnostics (IVD) devices involve various products such as:
• Health Monitor wearables (watches, patches, cuffs)
• Reagents and assay kits that include immunoassays, molecular tests and chemistry reagents. (Rapid disease detection kits)
• Instruments and analyzers that automate the sampling process. (Continuous Glucose Monitoring (CGM))
• Point of care (POC) rapid testing devices – blood sugar test, cholesterol test etc

IVD vs Other Medical Devices

Unlike therapeutic medical devices that directly interact with the patient’s body, In vitro diagnostic devices generate the diagnostic information guiding clinical decisions. IVDs faces risks from incorrect interpretation of results that can cause misdiagnosis or inappropriate treatment. The evidence is focused on clinical and analytical performances rather than direct clinical safety. Clinical performance is key, as it requires results that correlate gold standard treatments in clinical outcomes.

At Atlantia Clinical Trials, we rigorously test many of these devices against gold standard clinical testing to ensure that there is this correlation.

Types of IVD Devices

By Technology

• Immunoassays detect proteins and antibodies using antigen-antibody reactions like ELISA (Enzyme-Linked Immunosorbent Assay).
• Clinical chemistry methods measure substances like glucose and electrolytes.
• Molecular diagnostics analyzes nucleic acids via PCR and sequencing for personalized medicine.
• Hematology analyzers analyze blood cell components.
• Microbiology systems identify pathogens through culture and molecular methods.

By Setting

• Central laboratory-based testing happens in high-complexity labs with trained personnel.
• Point-of-care testing ensures quick results in clinical settings with simplified operation.
• Home testing involves a higher risk as it requires extensive human factor validation for untrained users.

By Clinical Application

They are deployed across:

• Infectious disease diagnostics to detect pathogens and guide therapy.
• Oncology diagnostics like tumor markers and companion diagnostics.
• Cardiovascular biomarkers to enable risk stratification.
• Diabetes monitors to provide real-time glucose data
• Genetic testing for carrier screening and pharmacogenomics.

Regulatory Framework for IVD Devices

How IVDs Are Regulated in the United States?

In the US, IVDs are regulated by the FDA as medical devices under the Federal Food, Drug and Cosmetic Act. They are classified under a three-tier system (Class I, II, III) based on risk with pathways including:

• 510(k) clearance for substantial equivalence is common for Class II devices.
• Premarket Approval (PMA) for high-risk Class III devices.
• De Novo classification provides a pathway for novel low-to-moderate risk devices.

EU IVDR Overview

The EU replaced IVDD (In Vitro Diagnostic Medical Device Regulation), introducing risk-based classifications (Class A-D), mandatory Notified Body assessment for most devices and increased requirements for clinical evidence.

The EU IVDR IVD classification ranges from Class A to Class D;

• Class A represents lowest-risk general In vitro diagnostics devices.
• Class B includes moderate-risk In vitro diagnostics devices used for many routine diagnostic uses.
• Class C covers serious diseases, STIs and oncology markers.
• Class D includes blood donor screening tests, serious disease detection and companion diagnostics.

Why Regulatory Strategy Must Be Defined Early

Early strategy is key in aligning development with requirements, helps in preventing development mistakes, avoids reclassification setbacks and optimize evidence generation. Defining the strategy early helps identify if prospective clinical studies are required as delays from mismatched planning can significantly extend timelines.

IVD Classification Explained

US Classification (Class I, II, III)

• Class I – Present minimal risk with exemption from premarket review.
• Class II – These are moderate risks and often require 510(k) clearance.
• Class III – They are high risk and require Premarket Approval (PMA) with extensive clinical data including blood donor screening tests.

EU IVDR Classification (Class A–D)

• Class A represents lowest-risk general devices.
• Class B involves devices with moderate risk.
• Class C covers high individual risk and moderate public health risk like oncology markers.
• Class D involves high individual and public health risks like blood donor screening tests, and serious disease detection.

Common Classification Pitfalls

Self-classification errors are often costly. These classification pitfalls include misjudging the intended purpose, misinterpreting IVDR classification rules and ignoring companion diagnostic implications.

Evidence Requirements for IVD Devices

Analytical Performance Studies

Analytical performance demonstrates that In vitro diagnostics (IVD) devices can provide accurate and reliable results under controlled conditions. They assess:

• Accuracy studies that compare devices’ results to the reference methods.
• Precision studies which evaluate repeatability and reproducibility across runs, days and operators.
• Analytical sensitivity that establishes the detection limit for the analyte.
• Analytical specificity that evaluates the assay’s ability to measure the intended analyte without interference from similar substances.
• Linearity studies that confirm accurate measurements across the reportable range
• Stability studies that demonstrate reagent shelf life and specimen stability under stable storage and transport conditions.

Clinical Performance Studies

An IVD clinical performance investigation shows that the IVD device’s results are meaningful linked with a specified clinical condition or clinical outcome in the target population providing evidence of safety and effectiveness in the intended use. They include:

• Diagnostic accuracy studies that measure the specificity and sensitivity regarding a clinical reference standard.
• Prospective clinical studies that collect and analyze samples based on existing protocols.
• Retrospective specimen studies that use archived clinical samples where collection is impractical.
• Method comparison studies that demonstrate the agreement with established diagnostic assays.

The performance metrics that are often evaluated include sensitivity, specificity, positive predictive value, negative predictive value and receiver operating characteristic curve analysis. Here, statistical planning is key as sample size calculations ensure that the specificity and sensitivity estimates have adequate precision. This is usually defined by confidence widths.

In cases of high-risk diagnosis like screening assays, there may be a need to submit additional evidence to demonstrate clinical utility. This ensures that the test results influence patient management and could improve their outcomes.

Usability & Human Factors (POC/Home Testing)

For point-of-care and home testing, regulators require human usability evidence that is important in mitigating risks from user errors like misinterpretation or improper sampling.

These studies assess whether target users including healthcare professionals or laypersons can operate the device properly and interpret the results. The common usability assessments evaluate:

• Comprehension of instructions for use
• Test executions steps
• Sample collection procedures
• Result interpretation
• Potential use errors

The human factors studies are key for self-tests, rapid antigen diagnostics and in decentralized testing environments where accurate laboratory training is required.

Poor usability can cause misinterpretation or lead to incorrect results. Regulators consider this a significant safety risk.

Software & Algorithm Validation

Most modern IVD systems use and depend on software for data interpretation, algorithmic result generation or signal processing and they require specialized validation. The algorithmic training and validation datasets must be diverse and inclusive. Performance across demographic subgroups must address the equity concerns. Cybersecurity controls and documentation demonstrate appropriate security controls.

For AI-driven diagnostics, additional evidence is necessary to show the algorithmic transparency, dataset representatives and consistent performance across populations.

IVD Development Lifecycle

Concept & Feasibility

The concept phase establishes clinical need with exploration of new biomarkers, reagents and technology. The market assessment identifies unmet needs and commercial opportunities. Feasibility studies review the selection of these reagents and assess development of early prototypes to demonstrate functionality.

Design & Risk Management

The project proceeds into the formal design controls after confirming feasibility. The majority of the IVD regulatory requirements are embedded here.

The design controls require a systemic IVD development process from the user’s needs through validation. Risk management aligns with ISO 14971 to identify hazards, implement controls and estimate risks.

For the IVDs, hazard analysis focuses on analytical errors, result misinterpretation and device misuse and specimen handling issues. It is important to maintain traceability between design inputs, risk controls and testing activities for regulatory documentation.

Verification & Validation

Verification confirms that design outputs meet existing specifications through analytical performance testing. Validation confirms that In vitro diagnostics (IVD) devices fulfil user needs in real clinical settings. It often involves an IVD clinical performance study that evaluates clinical relevance and diagnostic accuracy.

Process validation also ensures that manufacturing processes produce devices that meet existing standards consistently.

Regulatory Submission Preparation

The technical documentation required for the IVD approval process is compiled in this final stage. It involves clinical and analytical performance data, design history records, and quality risk management files.

These documents must demonstrate compliance with ISO 13485. Conducting pre-submission meetings with regulators can aid in clarifying expectations and handling potential issues before any submission. This will improve the chances of a successful regulatory review and CE marking for IVD devices.

Quality Management & Post-Market Requirements

Quality Management Systems (ISO 13485)

A quality management system is key for manufacturers of IVD devices. The international standard ISO 13485 establishes the guidelines for maintaining control over the design, manufacturing and post-market activities.

Key elements of a compliant quality system include:

• Document and change control
• Supplier qualifications and purchasing controls.
• Traceability of the components
• Corrective and preventive actions (CAPA)
• Internal audits and reviews.

The processes ensures that IVD devices are consistently developed while maintaining existing standards.

Post-Market Surveillance (PMS)

This process involves collecting and analysing real-world performance data after getting the device in the market. The activities involved include complaint handling, trend monitoring and Post-Market Performance Follow-Up (PMPF) in case additional evidence is needed.

Manufacturers must also conduct vigilance reporting for serious incidents and implement corrective actions to guarantee safety and performance under the In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.

Common Challenges in IVD Development

• IVDR notified body capacity constraints are creating delays in accessing European markets. This makes early engagement essential.
• Specimen sourcing involves the ethical collection of rare clinical samples especially emerging pathogens.
• Regulatory reclassification can end programs when the intended use is changed.
• Software updates and regulatory impact generate regulatory change-control dilemmas with the possibility of any minor changes triggering reassessment.
• Scaling manufacturing without performance drift requires process validation to prove consistent analytical and clinical performance at a commercial scale.

How a CRO Supports IVD Development?

A Contract Research Organization (CRO) like Atlantia provides specialized expertise throughout the IVD development process. This will help developers generate scientific evidence required for market authorization.

When to Engage a CRO?

Early engagement during study design provides the maximum value. They aid in site management, sample acquisition, protocol development and statistical planning. CROs provide regulatory intelligence on the evolving guidelines and authority expectations.

How Clinical & Analytical Study Design Impacts Approval?

The quality of the study design affects the success of the IVD approval process. Poor and inconclusive results are yielded due to inadequate samples, poorly defined endpoints or inappropriate reference standards.

Adherence to protocols and data quality ensures study credibility through good clinical practice compliance.

Value of Integrated Clinical & Regulatory Expertise

At Atlantia Clinical Trials, we utilize clinical capabilities with extensive regulatory expertise to ensure that the studies directly address the regulatory requirements. Submission support including technical file preparation and Notified Body Management accelerates the market authorization.

Frequently Asked Questions

What is an IVD device?

It is a device that examines specimens taken from the human body to provide diagnostic and monitoring information for medical decision making.

What classification is my IVD device?

Classification is dependent on the intended use, clinical significance, and the risk of incorrect results. The EU IVDR classification groups these devices from Class A-D while the US uses Classes I-III.

How long does IVD approval take?

US 510(k) reviews usually take 3-6 months after submission, although the total time from start of study to approval usually takes 12-24 months. EU IVDR timelines are dependent on Notified Body capacity and classification with Class D and C devices requiring 9-18 months from submission to CE marking for IVD devices. Timelines are wholly dependent on device type, NB capacity and availability of supporting clinical evidence and so can vary considerably.

What evidence is required for CE marking under IVDR?

In vitro diagnostics (IVD) devices continue to evolve rapidly with molecular, AI and point-of-care technologies. IVDR requires analytical performance data, clinical performance studies, risk management documentation, ISO 13485 certification and post-market surveillance plans. The higher classification devices require more extensive clinical performance studies. For organizations navigating IVD regulatory requirements, EU IVDR IVD classification, or designing IVD clinical performance studies, a proactive and integrated strategy remains the best path to CE marking for IVD devices and global approval.